Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.

ABSTRACT:

Background

Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the kidneys. Their use in dialysis patients is discouraged because these drugs can bioaccumulate to precipitate inadvertent bleeding. We wanted to determine whether prescription of dabigatran or rivaroxaban was occurring in the dialysis population and whether these practices were safe.

Methods and results

Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation. Poisson regression compared the rate of bleeding, stroke, and arterial embolism in patients who started dabigatran, rivaroxaban, or warfarin. The first record of dabigatran prescription among hemodialysis patients occurr

SUBMITTER: Chan KE 

PROVIDER: S-EPMC4363265 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature